价格

Cara Therapeutics

ACTIVE

400 Atlantic St Ste 500, 康涅狄格州费尔菲尔德县, 康涅狄格州, 美国www.caratherapeutics.comPublic55 名员工成立于: 2004-07-020亿美元

别名:

cara therapeutics inc

cara-us

cara

CARA Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors (KORs). Its portfolio includes opioid-based products, anesthetic-based drugs, and analgesics that targets to alleviate itch and pain. The company was founded by Derek T. Chalmers, Michael E. Lewis, and Frederique Menzaghi on July 2, 2004 and is headquartered in Stamford, CT.

概览

试验阶段分布

阶段

试验数

占比

1 期

38.9%

2 期

36.1%

3 期

22.2%

试验状态分布

进行中（未招募）

30.6%

Approved For Marketing

2.8%

已完成

52.8%

终止

13.9%

相关临床试验

该机构主办的试验（36）

Study to Evaluate the Efficacy and Safety of Oral Difelikefalin for Moderate to Severe Pruritus in Subjects With Notalgia Paresthetica

This is a clinical trial (study), to be conducted in several clinical sites worldwide, of an oral study drug which will be investigated in adult patients with moderate to severe pruritus (itching) associated with Notalgia Paresthetica to assess if it's effective and safe.

A Placebo-controlled 12-Week Study to Evaluate the Safety and Efficacy of Oral Difelikefalin in Advanced Chronic Kidney Disease Subjects with Moderate-to-Severe Pruritus with an up to 52-Week Long-term Extensio

1 期

进行中（未招募）

Dec 2022400 名受试者

A Placebo-controlled 12-Week Study to Evaluate the Safety and Efficacy of Oral Difelikefalin in Advanced Chronic Kidney Disease Subjects with Moderate-to-Severe Pruritus and not on Dialysis with an up to 52-Week Long-term Extensio

1 期

进行中（未招募）

Nov 2022400 名受试者

A Placebo-controlled 12-Week Study to Evaluate the Safety and Efficacy of Oral Difelikefalin in Advanced Chronic Kidney Disease Subjects with Moderate-to-Severe Pruritus with an up to 52-Week Long-term Extensio

1 期

进行中（未招募）

Nov 2022400 名受试者

CR845-310302: A Study to Evaluate the Safety and Efficacy of Difelikefalin in Advanced Chronic Kidney Disease Patients With Moderate-to-Severe Pruritus

Study to Evaluate the Efficacy and Safety of Oral Difelikefalin as Adjunct Therapy to a Topical Corticosteroid for Moderate to Severe Pruritus in Subjects With Atopic Dermatitis

A Study to Evaluate the Safety and Efficacy of Difelikefalin in Advanced Chronic Kidney Disease Patients With Moderate-to-Severe Pruritus

第 1 页，共 5 页

药物批准

暂无批准数据

资讯

Tvardi Therapeutics Completes Merger with Cara, Advances STAT3 Inhibitor Programs for Fibrosis-Driven Diseases

- Tvardi Therapeutics has completed its merger with Cara Therapeutics, creating a Nasdaq-listed company focused on developing STAT3 inhibitors for fibrosis-driven diseases, with shares trading under the ticker "TVRD." - The combined company has secured approximately $52 million in funding through the merger and a private placement, providing runway into the second half of 2026 through two anticipated Phase 2 data readouts. - Tvardi's lead clinical programs include Phase 2 trials of its oral STAT3 inhibitor TTI-101 in idiopathic pulmonary fibrosis (data expected 2H 2025) and hepatocellular carcinoma (data expected 1H 2026).

Apr 15, 2025

返回机构列表